Hanall Biopharma KRX:009420KOSPI

한올바이오파마 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days27
DART filings, 7 days1
Articles tracked132since Sep 11

In Q3 2026, Hanall Biopharma reported revenue of ₩39.9bn, down 2.2% year on year, and operating profit of ₩1.3bn. Hanall Biopharma (한올바이오파마) appeared in 27 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 10 with 21 articles. The most common catalyst was clinical & approvals (2). It was most often mentioned alongside Jeil Pharmaceutical and MedPacto.

Hanall Biopharma at a glance from DART filings

Results trend
Operating profit in 3 of the last 4 quarters; Q3 2026 operating profit of ₩1.3bn fell from the previous quarter.
Ownership changes
1 5%-holder and insider ownership reports in the past 120 days (0 increases, 1 decreases).

Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.

Hanall Biopharma today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Nov 16 Quarterly report filing deadlinetoday · period ending Sep 2026

Dates Hanall Biopharma stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

Hanall Biopharma quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩39.9bn-2.2%₩1.3bn
margin 3.2%
₩3.1bn
Q2 2026₩44.3bn+8.8%₩5.6bn
margin 12.6%
−₩19.2bn
Q1 2026₩40.0bn+10.7%₩839m
margin 2.1%
₩275m
Q4 2025 derived₩37.5bn+3.1%−₩2.0bn
margin −5.4%
−₩6.2bn
Q3 2025₩40.8bn+10.8%₩349m
margin 0.9%
₩299m
Q2 2025₩40.7bn+28.8%₩1.1bn
margin 2.8%
₩599m
Q1 2025₩36.2bn+6.0%−₩394m
margin −1.1%
−₩208m
Q4 2024 derived₩36.4bn+14.8%₩2.7bn
margin 7.5%
₩1.6bn

Hanall Biopharma ranks #1056 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Hanall Biopharma top stories 2 weeks, by number of outlets

  1. 1
    Hanoll Biopharma's Imeroprobbat meets primary evaluation endpoint in refractory rheumatoid arthritis Phase 1 trial
    3 outlets · 3 articlesFirst report Nov 10 09:51 스페셜타임스Clinical trial
  2. 2
    Hanall Biopharma says Aimiroprubart proves efficacy in intractable rheumatoid arthritis
    3 outlets · 3 articlesFirst report Nov 10 08:14 아시아경제
  3. 3
    Han-all Biopharma surges 20% in pre-market trading on Phase 2b success news
    2 outlets · 2 articlesFirst report Nov 10 08:38 한국경제
  4. 4
    Hanall Biopharm jumps 21% on successful rheumatoid arthritis clinical trial
    2 outlets · 2 articlesFirst report Nov 10 09:26 아이뉴스24
  5. 5
    Hanall Biopharm's licensed-in new drug shows effectiveness in intractable rheumatoid arthritis
    1 outlets · 1 articlesFirst report Nov 10 08:59 서울경제Licensing deal
  6. 6
    Shinhan Securities lowers Hanall Biopharma target price citing halted new drug CLE development
    1 outlets · 1 articlesFirst report Nov 10 08:52 연합뉴스경제

Latest Hanall Biopharma news Korean headlines